BACKGROUND: Lipid modification therapy (LMT) produces cardiovascular benefits principally through reductions in low density lipoprotein cholesterol. While recent evidence, using data from 454 participants in the Framingham Offspring Study, has suggested that increases in high density lipoprotein cholesterol (HDL-C) are also associated with a reduction in cardiovascular outcomes, independently of changes in low density lipoprotein cholesterol, replication of this finding is important. The authors therefore present further results using data from the EPIC-Norfolk (UK) and Rotterdam (The Netherlands) prospective cohort studies. METHODS: A total of 1148 participants, 446 from the EPIC-Norfolk and 702 from the Rotterdam study, were assessed for lipids before and after starting LMT. Subsequent risk of cardiovascular events, ascertained through linkage with mortality records and hospital databases, was investigated using Cox proportional hazards regression. Random effects meta-analysis was used to combine results across studies. RESULTS: Based on combined data from the EPIC-Norfolk and Rotterdam studies there was some evidence that change in HDL-C resulting from LMT was associated with reduced cardiovascular risk (HR per pooled SD (=0.34 mmol/l) increase=0.74, 95% CI 0.56 to 0.99, adjusted for age, sex and baseline HDL-C). However, this association was attenuated and was not (statistically) significant with further adjustments for non-HDL-C and for cigarette smoking history, prevalent diabetes, systolic blood pressure, body mass index, use of antihypertensive medication, previous myocardial infarction, prevalent angina and previous stroke (0.92, 0.701.20). CONCLUSIONS: Following adjustment for conventional non-lipid risk factors of cardiovascular disease, this study provides no evidence to support a significant benefit from increasing HDL-C independent of the effect of lowering non-HDL-C.
BACKGROUND: Lipid modification therapy (LMT) produces cardiovascular benefits principally through reductions in low density lipoprotein cholesterol. While recent evidence, using data from 454 participants in the Framingham Offspring Study, has suggested that increases in high density lipoprotein cholesterol (HDL-C) are also associated with a reduction in cardiovascular outcomes, independently of changes in low density lipoprotein cholesterol, replication of this finding is important. The authors therefore present further results using data from the EPIC-Norfolk (UK) and Rotterdam (The Netherlands) prospective cohort studies. METHODS: A total of 1148 participants, 446 from the EPIC-Norfolk and 702 from the Rotterdam study, were assessed for lipids before and after starting LMT. Subsequent risk of cardiovascular events, ascertained through linkage with mortality records and hospital databases, was investigated using Cox proportional hazards regression. Random effects meta-analysis was used to combine results across studies. RESULTS: Based on combined data from the EPIC-Norfolk and Rotterdam studies there was some evidence that change in HDL-C resulting from LMT was associated with reduced cardiovascular risk (HR per pooled SD (=0.34 mmol/l) increase=0.74, 95% CI 0.56 to 0.99, adjusted for age, sex and baseline HDL-C). However, this association was attenuated and was not (statistically) significant with further adjustments for non-HDL-C and for cigarette smoking history, prevalent diabetes, systolic blood pressure, body mass index, use of antihypertensive medication, previous myocardial infarction, prevalent angina and previous stroke (0.92, 0.701.20). CONCLUSIONS: Following adjustment for conventional non-lipid risk factors of cardiovascular disease, this study provides no evidence to support a significant benefit from increasing HDL-C independent of the effect of lowering non-HDL-C.
Authors: Elena Burillo; Eva Maria Andres; Rocio Mateo-Gallego; Sarah Fiddyment; Estibaliz Jarauta; Ana Cenarro; Fernando Civeira Journal: Heart Date: 2010-09 Impact factor: 5.994
Authors: M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen Journal: N Engl J Med Date: 1987-11-12 Impact factor: 91.245
Authors: H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader Journal: N Engl J Med Date: 2011-01-13 Impact factor: 91.245
Authors: Min Jun; Celine Foote; Jicheng Lv; Bruce Neal; Anushka Patel; Stephen J Nicholls; Diederick E Grobbee; Alan Cass; John Chalmers; Vlado Perkovic Journal: Lancet Date: 2010-05-10 Impact factor: 79.321
Authors: James D Otvos; Dorothea Collins; David S Freedman; Irina Shalaurova; Ernst J Schaefer; Judith R McNamara; Hanna E Bloomfield; Sander J Robins Journal: Circulation Date: 2006-03-13 Impact factor: 29.690
Authors: Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman Journal: Eur J Epidemiol Date: 2009 Impact factor: 8.082
Authors: Chantal Kopecky; Michael Haidinger; Ruth Birner-Grünberger; Barbara Darnhofer; Christopher C Kaltenecker; Gunther Marsche; Michael Holzer; Thomas Weichhart; Marlies Antlanger; Johannes J Kovarik; Johannes Werzowa; Manfred Hecking; Marcus D Säemann Journal: J Am Soc Nephrol Date: 2014-07-28 Impact factor: 10.121
Authors: Chantal Kopecky; Bernd Genser; Christiane Drechsler; Vera Krane; Christopher C Kaltenecker; Markus Hengstschläger; Winfried März; Christoph Wanner; Marcus D Säemann; Thomas Weichhart Journal: Clin J Am Soc Nephrol Date: 2014-11-25 Impact factor: 8.237
Authors: S Matthijs Boekholdt; Benoit J Arsenault; G Kees Hovingh; Samia Mora; Terje R Pedersen; John C Larosa; K M A Welch; Pierre Amarenco; David A Demicco; Andrew M Tonkin; David R Sullivan; Adrienne Kirby; Helen M Colhoun; Graham A Hitman; D John Betteridge; Paul N Durrington; Michael B Clearfield; John R Downs; Antonio M Gotto; Paul M Ridker; John J P Kastelein Journal: Circulation Date: 2013-08-21 Impact factor: 29.690
Authors: Chantal Kopecky; Sanam Ebtehaj; Bernd Genser; Christiane Drechsler; Vera Krane; Marlies Antlanger; Johannes J Kovarik; Christopher C Kaltenecker; Mojtaba Parvizi; Christoph Wanner; Thomas Weichhart; Marcus D Säemann; Uwe J F Tietge Journal: J Am Soc Nephrol Date: 2016-09-09 Impact factor: 10.121